Celecoxib and Muscle Growth: Current Evidence
Yes, there is direct evidence that celecoxib impairs muscle growth in human muscle cells, but this effect appears to be independent of its COX-2 inhibitory action and may not reflect the complete clinical picture.
Key Research Findings
The most relevant study 1 directly examined celecoxib's effects on primary human skeletal muscle cells in 2022. This research demonstrated that celecoxib significantly impaired:
- Myoblast proliferation and viability (dose-dependent reduction)
- Muscle cell fusion (decreased ability of cells to merge)
- Myotube area (smaller muscle fiber formation)
- Anabolic signaling pathways (reduced phosphorylation of AKT, p70S6K, S6, and ERK)
- Mitochondrial function (decreased membrane potential, respiration, and citric acid cycle intermediates)
Critical Mechanistic Insight
The muscle growth impairment occurred independent of COX-2 inhibition. When researchers used NS-398 (a pure COX-2 inhibitor) as a control, it had no effect on any of these muscle parameters 1. This suggests celecoxib's negative effects on muscle cells involve off-target mechanisms beyond its intended anti-inflammatory action.
Contradictory Evidence
However, a 2025 animal study 2 presents opposing findings, showing that celecoxib:
- Enhanced oxidative muscle fiber formation
- Increased lean mass by >9.35% and grip strength by <18.0%
- Improved mitochondrial content by 32.8%
- Activated PROKR1 signaling pathways that promote muscle function
This study suggests celecoxib may act as a PROKR1 agonist with potential muscle-enhancing properties in mice.
Clinical Context and Interpretation
Important Caveats
In vitro vs. in vivo discrepancy: The human cell culture study 1 shows direct cellular toxicity, while the animal study 2 shows systemic benefits. Real-world effects may differ from isolated cell experiments.
Dosing considerations: The negative effects in human cells were dose-dependent. Clinical doses may not reach the concentrations that caused significant impairment in cell culture.
Study populations: The animal study used developmental exposure (prenatal through weaning), which may activate different pathways than adult treatment.
No human clinical trials: Neither study directly measured muscle hypertrophy outcomes in humans taking celecoxib for pain management.
Clinical Safety Profile
The broader safety literature 3 from 2025 shows celecoxib is generally well-tolerated for musculoskeletal conditions, though this focused on cardiovascular, gastrointestinal, and renal outcomes rather than muscle growth specifically.
Practical Recommendations
For individuals prioritizing muscle hypertrophy (athletes, bodybuilders, rehabilitation patients):
- Consider alternative pain management when possible, given the direct cellular evidence of impaired muscle protein synthesis and mitochondrial function
- If celecoxib is necessary, use the lowest effective dose for the shortest duration 4, 5
- Avoid chronic use during periods of active muscle building or recovery from injury
- Monitor for reduced training adaptations or slower recovery
Alternative approaches for musculoskeletal pain:
- Acetaminophen as first-line (though less effective for inflammation) 6, 7
- Non-selective NSAIDs like naproxen may have different muscle effects, though this hasn't been directly studied
- Non-pharmacological interventions (physical therapy, exercise modification)
Bottom Line
The 2022 human cell study 1 provides concerning mechanistic evidence that celecoxib directly impairs muscle cell proliferation, differentiation, and anabolic signaling through COX-2-independent pathways. While contradicted by one animal study showing benefits 2, the human cellular data suggests caution when muscle growth is a priority. Until clinical trials directly assess muscle hypertrophy outcomes in humans taking celecoxib, those focused on maximizing muscle gains should consider alternative pain management strategies when feasible.